Thyrocare Technologies Limited has informed the Exchange about an amendment to the Code of Conduct of the Company for Regulating, Monitoring, and Reporting of Trading by Designated Persons and their Immediate Relatives under the SEBI (Prohibition of Insider Trading) Regulations, 2015..
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.1 pts more than Nifty Microcap 250 and 11.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies reported strong Q1 FY26 results. Standalone revenue from operations rose to Rs. 178.89 crores (up ~24.5% from Rs. 143.63 crores in Q1 FY25), with profit after tax jumping to Rs. 36.05 crores (up ~43% from Rs. 25.15 crores). Consolidated revenue grew ~23% to Rs. 193.03 crores and consolidated PAT surged ~60% to Rs. 38.29 crores. Standalone EPS stood at Rs. 6.78 versus Rs. 4.75 in the year-ago quarter. The board also approved the appointment of Mr. Vikram Gupta as the new CFO (replacing Mr. Alok Kumar Jagnani, who moved to Group CFO at API Holdings), appointment of Mr. Jagnani as a Non-Executive Director, and accepted the resignation of Mr. Hardik Kishor Dedhia as Non-Executive Director. Additionally, the company increased its stake in Thyrocare Tanzania to 57.25% (from 50%), making it a wholly consolidated subsidiary, and amended its Insider Trading Code of Conduct as required under SEBI regulations.
Strong double-digit revenue and profit growth in Q1 FY26 is a positive signal for shareholders, reflecting robust demand in the diagnostics business. The CFO transition appears orderly with an internal appointment, and there is no negative auditor observation, supporting a stable outlook for the stock.